ARCHIVES

FDA says official spoke on own behalf in admonition to The Cancer Letter. Association of Health Care Journalists asks FDA official to rescind her rebuke.

This article is from The Cancer Letter archive.

Vol. 31 No. 11 | March 18, 2005

Download PDF Visit The Full Archive

Related Articles

Advisors Discuss NCI Intramural Program In Closed Session, Defend Process

December 16, 1994

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005

President, First Lady Visit Clinical Center, Hail ‘Compassion’

January 12, 1990

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Oncologists Don’t Demand Increased Survival When Ordering Expensive Drugs, Survey Finds

April 13, 2012

Some Tumors Show Partial Response To Drug Combo

January 27, 2006